Healthcare investing offers defensive characteristics during market turbulence, yet regulatory uncertainty and political risk can trigger sudden selloffs. For investors seeking pure healthcare exposure without picking individual stocks, Fidelity MSCI Health Care Index ETF (NYSEARCA:FHLC) provides a low-cost entry point to this complex sector.
What FHLC Delivers: Sector Exposure With a Concentration Problem
FHLC tracks the MSCI USA IMI Health Care Index, providing exposure to U.S. healthcare companies across pharmaceuticals, biotechnology, medical devices, and health insurance. With an expense ratio of just 0.084%, the fund undercuts many competitors while maintaining over 80 holdings. The return engine is straightforward: capital appreciation from underlying stock holdings plus modest dividend income from mature healthcare companies.
However, concentration risk looms large. Eli Lilly (NYSE:LLY | LLY Price Prediction) represents over 13% of the portfolio, meaning FHLC’s performance has become increasingly tied to GLP-1 obesity drugs. The stock has surged 46% over the past year and trades near its 52-week high. When a single holding approaches one-seventh of your portfolio, you’re making a bet whether you intended to or not. The top five holdings also include UnitedHealth (NYSE:UNH), Johnson & Johnson (NYSE:JNJ), Merck (NYSE:MRK), and AbbVie (NYSE:ABBV).
Recent Performance Masks Long-Term Underperformance
FHLC has delivered strong short-term results, gaining 5.3% over the past month and 17.9% over the past year, outpacing the S&P 500 in both periods. But zoom out and the picture changes dramatically. Over five years, FHLC returned 42.6% compared to the S&P 500’s 84.5%. Over ten years, the gap widens to 154% versus 235%.
This underperformance reflects healthcare’s challenges: drug pricing pressures, slower innovation cycles outside oncology and rare diseases, and managed care’s struggles with rising medical costs. The recent momentum suggests potential sector rotation, but buying after outperformance carries risk.
The Tradeoffs: Policy Risk and Modest Income
Healthcare investors must accept political and regulatory uncertainty. Prediction markets currently assign an 87.5% probability that enhanced ACA premium tax credits will expire by the end of January 2026. This would pressure health insurers like UnitedHealth (4.5% of FHLC), which has already declined 31% over the past year. Meanwhile, drug pricing negotiations under Medicare continue to create headline risk for pharmaceutical holdings.
Income seekers will find FHLC’s 1.33% yield underwhelming compared to broader market alternatives. While the fund has grown dividends at roughly 4.6% annually over five years, this barely keeps pace with inflation and lags the income potential of other defensive sectors.
Who Should Avoid FHLC
Growth-focused investors seeking maximum capital appreciation should look elsewhere. Healthcare’s long-term underperformance versus the broader market makes FHLC unsuitable for aggressive portfolios. Similarly, retirees prioritizing income generation will find better yields in other sectors without sacrificing stability.
Consider Vanguard Health Care ETF Instead
Investors comparing healthcare sector funds should examine Vanguard Health Care ETF (NYSEARCA:VHT) as an alternative. VHT charges an even lower expense ratio of 0.09% versus FHLC’s 0.084%, a negligible difference. More importantly, VHT holds $20.4 billion in assets compared to FHLC’s $2.9 billion, providing superior liquidity and tighter bid-ask spreads. VHT also offers slightly higher dividend yield at 1.38%. The funds hold similar top positions with Eli Lilly leading both, but VHT’s larger asset base and longer 22-year track record since 2004 provide additional confidence for long-term holders.
FHLC works best as a tactical healthcare sector allocation for investors who want low-cost exposure and believe the sector’s recent momentum will continue, but the concentration risk and historical underperformance demand careful position sizing.
Top Gaining Stocks
Top Losing Stocks